On January 8, 2021 Roivant Sciences reported that Vivek Ramaswamy, Founder and Chief Executive Officer of Roivant, will present an overview of recent milestones and future directions for the business at the 39th Annual J.P. Morgan Healthcare Conference (Press release, Roivant Sciences, JAN 8, 2021, View Source [SID1234573719]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentation will occur on Monday, Jan. 11, 2021, at 8:40 a.m. ET. A live webcast for conference participants will be available here.
Recent milestones at Roivant include the following:
Targeted protein degradation platform unveiled, powered by VantAI and supported by a $200 million strategic investment from SK Holdings
Positive Phase 3 data from Dermavant’s pivotal PSOARING trials of tapinarof presented at the European Academy of Dermatology and Venereology (EADV) Virtual Congress
Positive clinical data from ARU-1801, Aruvant’s investigational one-time gene therapy for sickle cell disease, presented at the American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting
Recent milestones at Sumitovant, formed through a 2019 strategic alliance with Sumitomo Dainippon Pharma, include:
FDA approval of relugolix for the treatment of advanced prostate cancer
FDA approval of vibegron for the treatment of overactive bladder
$4.2 billion Myovant partnership with Pfizer for the continued development and commercialization of relugolix in the US and Canada
Definitive agreement for Sumitovant to acquire all outstanding shares of Urovant